Pharmaceutical Executive May 2014

May 2014 | Volume 0, Issue 0
From the Editor
Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.
Despite provisions in the Affordable Care Act that require qualified health plans to cover 'basic' benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.
By Pharmaceutical Executive Editors
MNCs can learn a lot from generic companies in their strategic approaches to emerging markets.
We check back with previous Pharm Exec Brand of the Year winners to see how things are going.
By Pharmaceutical Executive Editors
Digital technology has changed the risk relationship between brands, HCPs, and patients – it's vital to get that technology working right the first time.
By Pharmaceutical Executive Editors
Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth.
Pharm Exec's Brand of the Year recipients for 2014 are multiple sclerosis treatment Copaxone and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs.
lorem ipsum